A control study trial involving 36 selected healthy vaccinated, experimentally infected with Echinococcus granulosus (10000 viable protoscoleces/2 successive days for each animal) was carried out. The study was designed to compare the efficacy of 4 tested drugs in a new paste formulation and various concentrations of praziquantel (2.5-10 mg PZQ/kg B.W.) and Droncit® tablets as a reference drug, in treatment of E. granulosus infection in dogs. A single or fractionated administered dose of treatment with these oral pastes or Droncit® tablets (5 mg PZQ/kg B.W.) gave a similar degree of efficacy (100% clearance) against immature forms of E. granulosus. According the experimental design, animals were examined after necropsy for worm burdens at 5, 7 & 9 days post treatment. Adverse reactions or side effects were not observed in the treated dogs. No serious risk was involved in administering the tested drugs. The administered pastes given orally were well tolerated without observable adverse effects. These new pharmaceutical preparations of praziquantel were effective and extremely convenient to administer for treatment of E. granulosus infection in dogs.